There are currently 1553 clinical trials in Baltimore, Maryland looking for participants to engage in research studies. Trials are conducted at various facilities, including Johns Hopkins University, Johns Hopkins Hospital, University of Maryland and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
NCT05780814
Recruiting
The investigators propose a randomized controlled clinical trial in 250 women with a history of early stage breast cancer who are overweight or obese with insomnia to test whether a brief, cognitive-behavioral intervention for insomnia (CBT-I) prior to behavioral weight loss (CBT-I+BWL) is superior to a sleep education control (EDU) condition followed by behavioral weight loss (EDU+BWL). The investigators will measure outcomes at baseline, 8 weeks (after completing CBT-I or EDU and prior to BWL)... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Sidney Kimmel Comprehensive Cancer Center, the Avon Foundation Breast Center at Johns Hopkins, Baltimore, Maryland +1 locations
Conditions: Breast Cancer, Insomnia, Weight Gain
Register for Updates
Comparison of Two Pulmonary Embolism Treatments
NCT05684796
Recruiting
The primary objective of this trial is to evaluate the safety and efficacy of treatment with anticoagulation alone versus anticoagulation and mechanical aspiration thrombectomy with the Indigo Aspiration System for the treatment of intermediate-high risk acute pulmonary embolism (PE).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/05/2025
Locations: University of Maryland, Baltimore, Maryland
Conditions: Pulmonary Embolism Acute
Register for Updates
CAPABLE Transplant
NCT06326905
Recruiting
The purpose of this mixed methods study is to adapt CAPABLE as CAPABLE Transplant to accomplish two things: 1) To resolve barriers to being classified as active on the Kidney Transplant (KT) waitlist and 2) as a surgical prehabilitation intervention targeting the pre-frail/ frail KT waitlist population. It consists of two phases- an open label pilot and a randomized waitlist control trial.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/05/2025
Locations: Johns Hopkins School of Nursing, Baltimore, Maryland
Conditions: Quality of Life, Depression, End Stage Renal Disease, Disability Physical
Register for Updates
Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)
NCT05051033
Recruiting
This is a prospective, multicenter, open-label, randomized trial comparing mitral valve (MV) transcatheter edge-to-edge repair (TEER) to surgical repair (1:1 ratio) in patients with primary, degenerative mitral regurgitation (MR). The trial will be conducted in the U.S., Canada, Germany and the United Kingdom, and is designed as a strategy trial. Thus, all devices legally marketed for TEER of primary degenerative MR in a particular country are eligible to be used in this trial.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/05/2025
Locations: The Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Mitral Valve Regurgitation
Register for Updates
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
NCT03615235
Recruiting
The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from ki... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/04/2025
Locations: University of Maryland School of Medicine, Baltimore, Maryland +1 locations
Conditions: Kidney Diseases, Kidney Failure, Kidney Disease, Chronic
Register for Updates
APrevent-VOIS-Implant-002 - a Two-Part, Open-Label, Non-Randomized Multicenter Study
NCT05119842
Recruiting
This is a prospective, 2-part, multi-center, open-label, non-randomized clinical trial to assess safety and effectiveness of APrevent® VOIS Implants for the treatment of patients with Unilateral Vocal Fold Paralysis (UVFP). In total 30 evaluable patients are planned to be enrolled.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/04/2025
Locations: Greater Baltimore Medical Center, Baltimore, Maryland
Conditions: Paralysis, Unilateral, Vocal Cord
Register for Updates
Biodistribution and Pharmacokinetics of Pretomanid in Tuberculosis Patients Using 18F-Pretomanid PET
NCT05609552
Recruiting
This is an observational study that will examine the pretomanid pharmacokinetics (PK) in tuberculosis (TB) patients. Dynamic 18F-pretomanid PET/CT will be performed after intravenous injection of 18F-pretomanid to determine multi-compartment, noninvasive determination of pretomanid PK in TB patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Johns Hopkins Medical Institutions, Baltimore, Maryland
Conditions: Tuberculosis
Register for Updates
The Role of IL5 in Epithelial Cell Integrity
NCT05895929
Recruiting
The goal of this laboratory study is the examine the effect of mepolizumab drug on the health and function of the cells lining the human nasal airways in vitro cell culture derived from patients with chronic rhinosinusitis with nasal polyposis. The main questions the study aims to study are: 1. To see what mepolizumab does to suppress inflammation of the human cells. 2. To see what mepolizumab does to maintain barrier integrity of epithelial cells
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/04/2025
Locations: Johns Hopkins Bayview Medical Center, Baltimore, Maryland +1 locations
Conditions: Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis (Diagnosis)
Register for Updates
HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
NCT04131413
Recruiting
The primary goal of this phase I open label study is to determine the safety and tolerability of pNGVL4aCRTE6E7L2 DNA vaccine, as administered by intramuscular (IM) injection with TriGrid™ electroporation to both HIV- or HIV+ adult female subjects (≥ 19 years), with biopsy confirmed cervical intraepithelial (CIN) II or III that is human papillomavirus (HPV) 16+.
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
02/04/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
Register for Updates
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
NCT04620239
Recruiting
This is a phase 3, open label, single arm study of padeliporfin in the treatment of Upper Tract Urothelial Carcinoma (UTUC). The ENLIGHTED study will recruit patients with low-grade non-invasive upper tract urothelial carcinoma in either the kidney or the ureter. Patients will be treated with padeliporfin VTP in two phases: an Induction Treatment Phase and a Maintenance Treatment Phase and will be followed up for up to an additional 48 months in the long term (non intervention) follow up phase w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: The Johns Hopkins Hospital, The Sidney Kimmel Cancer Center, Baltimore, Maryland
Conditions: Transitional Cell Cancer of Renal Pelvis and Ureter
Register for Updates
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT05691504
Recruiting
This phase I trial tests the safety, side effects, and best dose of combination therapy with pelcitoclax (APG-1252) and cobimetinib in treating patients with ovarian and endometrial cancers that have come back after a period of improvement (recurrent). APG-1252 is a drug that inhibits activity of proteins that prevent cell death, leading to increased cell death and reduced cell growth. Cobimetinib is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a cla... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Conditions: Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Advanced Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Platinum-Resistant Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Register for Updates
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
NCT04877288
Recruiting
The purpose of this study is to evaluate the benefits and risks of conversion of existing adolescent kidney allograft recipients aged 12 to less than 18 years of age to a belatacept-based immunosuppressive regimen as compared to continuation of a calcineurin inhibitor-based regimen and their adherence to immunosuppressive medications.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
02/03/2025
Locations: Local Institution - 0017, Baltimore, Maryland
Conditions: Renal Allograft Recipients
Register for Updates